Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer...

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Growth factors regulate cell proliferation and survival.
• Chemotherapy drugs, like cis-diamminedichloroplatinum (cis-DDP), primarily induce apoptosis (programmed cell death).
• Ovarian cancer cells express the epidermal growth factor (EGF) receptor, and lysophosphatidic acid (LPA) is abundant in patient ascites.

Purpose of the Study:

• To investigate if EGF and LPA affect the efficacy of cis-diamminedichloroplatinum (cis-DDP) in killing ovarian cancer cells.
• To determine if these growth factors modulate cis-DDP-induced apoptosis in ovarian cancer.

Main Methods:

• Utilized the HEY ovarian cancer cell line.
• Assessed cell killing using colony-forming cell activity and dye reduction assays.
• Examined morphological changes, DNA release, and employed electron microscopy.

Main Results:

• Both EGF and LPA significantly decreased the ability of cis-DDP to kill HEY ovarian cancer cells.
• Evidence from morphological, DNA release, and electron microscopy studies indicated that EGF and LPA protect cells from cis-DDP-induced apoptosis.
• LPA and EGF interfere with the programmed cell death pathway triggered by cis-DDP.

Conclusions:

• Growth factors EGF and LPA can protect ovarian cancer cells from the cytotoxic effects of cis-DDP.
• The presence of LPA in ascites and EGF receptor expression in tumors suggests a role for growth factor-mediated chemoresistance in ovarian cancer prognosis.
• Modulation of cis-DDP-induced apoptosis by growth factors may contribute to the poor outcomes observed in ovarian cancer patients.